Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.
about
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaAssociation between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-AnalysisOptimizing the Clinical Use of VancomycinTemocillin revivedClinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot StudyPopulation pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolidImpact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infectionEvaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plaguePharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis modelPharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyIntra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infectionsUse of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenemEfficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection.Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.In vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic miceIn vivo pharmacodynamics of new lipopeptide MX-2401In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella speciesPharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States.An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.Teicoplanin dosing strategy for treatment of Staphylococcus aureus in Korean patients with neutropenic feverRefining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care unitsOnce-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaVancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalizationResponse of a clinical Escherichia coli strain to repeated cefquinome exposure in a piglet tissue-cage model.
P2860
Q22241905-DFA5B321-76A4-4E9D-B42F-8EB93DBA937FQ26770913-7D5E7A40-EF86-4D03-81A6-2CFDFDAA0F0BQ28069334-C86DFC55-9729-4CCA-A7CC-4317D155703AQ28304497-6243FFA9-826E-4580-B08A-6E903EDFC793Q28551453-5270BBC3-EF52-4920-B9A7-DCCD7253744FQ30316322-F62DDC7E-4770-4A7E-829B-C716FC642E8DQ33375091-DCD71506-4088-49F9-BAB6-2978DEE358FAQ33623078-AC2C36E5-589F-4985-B2B5-6BAF6F56752BQ33722108-91F89994-8F8F-4714-9818-AA92A2F0C598Q33770046-2E3AA626-E829-45AC-B9FB-7FF084E3E9B1Q33797936-8948E6BD-7D12-4A9E-84DF-BB49F34A2EE4Q33798021-6A927939-557B-4CD3-BCF9-1F1999A0DD75Q33826432-CBE452A3-28D4-48E0-A22E-FFA9AE679794Q33827819-4A6EFBA8-8D52-465A-9B8D-4B9014B05FDCQ33876454-00A24A39-53F2-435B-AC64-E72B558764BFQ33881584-5B36D604-6890-4450-A208-A1073F7A8D38Q33935441-DABD9EAD-4024-4DE5-8DE7-938522E3EE20Q34077052-0E9E0FF4-3B1D-411E-A338-6413D0423D8EQ34077095-99FDF634-5106-4B5F-AC26-35758677A0A1Q34108660-F4A4B19B-14C0-4BB1-BC08-C3963889631EQ34151164-8D1FC5ED-7F58-4944-9A6D-464173FB84E4Q34274190-8CDE494C-6F19-4B0C-A313-18AF61A3F4A6Q34299028-AD8EF2DD-BE57-4E85-86A9-A8B36236EC4EQ34309486-3F628DF1-6893-4321-A0D3-5AA52B6F8853Q34320027-4880F7D8-3F76-482C-AD87-9D49420EB177Q34509728-AE2A2C30-4D90-48CE-91BF-51007BCAF8E6Q34510488-63988541-7D44-40C5-97C3-DE1C4C1E8C54Q34541183-D568783E-B41F-4483-9330-13D3F933FC00Q34680546-00DBE997-68D3-421B-B660-679ADD725918Q34922218-2AAFDCC6-4897-4FBF-B1F4-C013A013A777Q34922257-20D9E819-CA3B-4C11-876F-479AC2262D36Q35014842-DADD75BB-270A-483F-B199-B8075A81DDC2Q35191519-38A63112-249A-4C8D-A0BF-A1E7ED853515Q35215457-93FBC947-C11A-4A84-860C-F67C5AB57C77Q35598479-1098787B-2BDF-4999-8A12-08B554AEB483Q35607636-AD84D63B-7651-4BA4-AE9F-646B1F34C30BQ35607715-4C48B7DD-69E5-4305-A3F5-F5289B8D9F1DQ35647785-12709069-8FA1-451C-9E71-2DDCF54B3FB4Q35689318-E6F3EEAA-5B22-4868-A62B-80A5F34CDD28Q35712872-620ABB9F-D2AA-4443-982C-09414E003A22
P2860
Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Basic pharmacodynamics of anti ...... glycopeptides, and linezolid.
@ast
Basic pharmacodynamics of anti ...... glycopeptides, and linezolid.
@en
type
label
Basic pharmacodynamics of anti ...... glycopeptides, and linezolid.
@ast
Basic pharmacodynamics of anti ...... glycopeptides, and linezolid.
@en
prefLabel
Basic pharmacodynamics of anti ...... glycopeptides, and linezolid.
@ast
Basic pharmacodynamics of anti ...... glycopeptides, and linezolid.
@en
P1476
Basic pharmacodynamics of anti ...... glycopeptides, and linezolid.
@en
P2093
William A Craig
P304
P356
10.1016/S0891-5520(03)00065-5
P577
2003-09-01T00:00:00Z